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he metabolic syndrome (MetS) is a cluster of inter-
related risk factors -including obesity, atherogenic 
dyslipidemia, hypertension, and insulin resistance, 
which exponentially increase the risk of developing cardio-
vascular disease and type 2 diabetes mellitus. The purpose 
of this cross-sectional study is to determine the prevalence of 
MetS according to the International Diabetes Federation (IDF) 
and the last harmonizing MetS criteria in adult individuals of 
both sexes from San José de Cúcuta, Colombia, a medium-
size city belonging to the North of Santander Department, 
with a population of 587.676 inhabitants according to the 
2005 census information conducted by the National Statistic 
Administrative Department (DANE) with a projection by 2017 
of 662.765 persons. Likewise, DANE projects that 68.5% 
(454.077 hab) of Cucutan population will be over 18 years 
by 2017, so that, using these data, the sample size for San 
José de Cúcuta is 2200 adult persons for a 95% confidence 
interval and a maximum accepted sampling error of 5%. 
Data derived from both, medical and laboratory examina-
tion (smoking habit, socioeconomic status, ethnicity, al-
cohol consumption, nutritional habits, physical activity by 
IPAQ, blood pressure, anthropometry, and blood chemis-
try and endocrinology panel) will be conducted by trained 
health professionals and medical students. 
There is a clear lack of evidence regarding the prevalence 
of cardio-metabolic risk factors and local cut-off points for 
biological quantitative variables i.e. abdominal circumfer-
ence, body mass index, fasting insulin, Homeostasis Model 
Assessment, among others. In the near future, this study 
will contribute for new evidence, providing first hand accu-
rate evidence about MetS behavior in our country.
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he metabolic syndrome (MetS) is a cluster of 
interrelated cardio metabolic risk factors -in-
cluding abdominal obesity, athero genic dyslip-
idemia, hypertension, and dysglycemia, driving to a 5-fold 
increase in T2DM risk, 2- to 4-fold increased risk of stroke, 
a 3 to 4-fold increased risk of myocardial infarction (MI), 
and 2-fold death risk when comparing with those with-
out MetS1-5. The major risk factors for developing MetS 
are physical inactivity and a diet high in fats and carbo-
hydrates, contributing to the two central clinical features, 
i.e. central obesity and insulin resistance (IR). Obesity is a 
key point to MetS development as it appears to precede 
the subsequent clustering of the other MetS components6. 
The results from both, the Third National Health and Nutri-
tion Examination Survey (NHANES III) and NHANES con-
tinuous trends show an alarming prevalence increase in 
MetS and obesity among USA population7. Regrettably, 
this picture closely mirrors the epidemiological behavior 
of this condition in most of westernized life styles coun-
tries leading a comprehensive research effort with the aim 
to elucidate its pathophysiology, fine molecular events 
and developmental determinants, time-spatial and ethnic 
frames, clinical features, risk profiles, and both – the set 
of diagnostic criteria and its ethnic-specific cut-off points- 
impacting on MetS prevalence and predictive its impact8. In 
this context, it is particularly remarkable the lack of cut-off 
points and reference intervals in each MetS component for 
Latin American (LA) population, a fact extremely necessary 
when considering the differ ent ethnic groups living in our 
countries, ranging from Hispanic-Whites, Amerindians, Af-
ro-Americans to a well-recognized American blended race, 
limiting the applicability of any MetS definition, as well as 
any preventive measure in our region9-13.
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The main purpose of this project is to determine the MetS 
prevalence in adult individuals from San José de Cúcuta, 
Colombia, according to the criteria proposed by: a) The In-
ternational Diabetes Federation8, b) The Third Report of the 
National Cholesterol Education Program Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Cho-
lesterol in Adults (ATP III)14, c) The harmonized MetS ac-
cording IDF/AHA/ADA/IAS/NHLBI,IASO-2009 (IDF-2009)15 
d) a novel MetS set of criteria derived from an exhaustive 
variable analysis in our locality, namely, fasting blood glu-
cose, abdominal circumference, blood pressure levels and 
Triacylglycerides/High density lipoproteins levels. Alongside, 
the specific objectives of the study are the following: A) to 
determine the prevalence of individual MetS components 
(T2DM, hypertension, hypertriacylglyceridemia, low c-HDL 
and abdominal obesity) B) To determine the cut-off points 
for waist circumference (WC), blood pressure, fasting blood 
glucose, Lipoprotein (a), serum triacylglycerides and high 
density protein (c-HDL), C) to analyze the behavior and de-
terminants of psychobiologic habits like alcohol consump-
tion, tobacco smoke, physical activity, total calories intake, 
feeding patterns and its relationship with MetS diagnosis. 
The association (or lack thereof) of family history of CVD 
with the occurrence of MetS and the calibrated Framing-
ham-Wilson risk score equation construction will be also 
analyzed. This work is meant to add a more profound 
knowledge of this noxa in our geography, developing bet-
ter tools for a proper preventive and curatives strategies. 
Study design, sample size calculation 
and sampling process 
This research project is a cross-sectional study based in a 
representative sample from the San José de Cúcuta, North 
of Santander Department, Colombia. According to the 
last Colombian census conducted by the National Statis-
tic Administrative Department (DANE) in 200516, San José 
de Cúcuta had a population of 587.676 inhabitants with 
a 2017 projection of 662.765 habitants, of which 68.5% 
will be over 18 years. Taking this information along with 
an expected prevalence of MetS in the adult population of 
27% (derived of small regional studies), an absolute preci-
sion between of 5%, a confidence level of 95%, and a 
design size effect of 2, the sample size estimate for our city 
is 1986 adult individuals, which will be proportionally dis-
tributed among ten “comunas” (districts equivalent) of the 
city. For the purpose of this study, a complex, multi-stage 
probability sampling design will be applied to select partici-
pants’ representative on the civilian (non-institutionalized) 
citizens, using a 4-stage sampling process with a similar 
methodology proposed by NHANES III17: During the first 
stage, the primary sampling units (PTU) are selected. These 
are geographic areas constituted by “barrios” (neighbor-
hoods) with a probability proportional to a measure of size 
(PPS) approach. In the second sampling stage, the PTU will 
be divided in blocks or their equivalent. As with each PSU, 
sample segments are selected with PPS. In the Stage 3, 
households within each segment are listed, and a sample is 
randomly drawn. In the stage 4, individuals are chosen to 
participate in the study from a list of all adult residents in 
selected households. A sample weight is assigned to each 
sampled person as a measure of the number of people 
in the population represented by that sample person, re-
flecting the unequal probability of selection, non-response 
adjustment, and adjustment to independent population 
controls. When unequal selection probability is applied, 
the sampling weights are used to produce an unbiased 
estimated. Finally, the selected individuals from each fam-
ily unit who fulfill the inclusion criteria will be invited to 
participate and inter viewed prior written consent sign, and 
subjected to a routine medical examination using a clinical 
chart as a data collecting tool. 
Measures to improve enrollment process 
The following measures will be taken to facilitate and en-
courage the participation of the selected individuals: a) 
paperwork explaining all process involved in patient evalu-
ation will be performed and given to the participants; b) 
involve ment of local health professionals will be guaran-
teed; c) invitations will be sent directly through the local 
community leaders, or through a professional social worker 
in primary health centers whom are part of the communi-
ties; d) the invitations will be confirmed by telephone; e) 
the evaluation site and blood samples will be taken as near 
as possible of the participant home (either in a school, lo-
cal community center, or primary care center). All data col-
lection will be conducted by health professionals, medical 
students, nutritionists, sociologist, psychologist, and nurses 
(previously trained), belonging to the “Endocrine and Met-
abolic Diseases Research Center” (CIEM), University of Zu-
lia, Venezuela, and the Altos Estudios de la Frontera (ALEF) 
research group, Cúcuta – Colombia.
Personnel training program
In order to get full trained personnel, special sessions re-
garding handle the electronic medical record software 
will be necessary, so that, the recollection of data like de-
mographics, family, and personal history was indeed accu-
rate. Also, a rigorous preparation and evaluation will be ap-
plied to all trainees, so that the anthropometric evaluation 
could be done swiftly and precisely; this included height, 
weight, and abdominal circumference. For the physical ex-
amination, special sessions on semiology maneuvers were 
done, so the proper and standardized protocol was fol-
lowed during this particular exam. All of these were super-
vised by a qualified instructor.
Variables definition and evaluation
Smoking habit: To define smoking habit, the Brinkman in-
dex was applied, which is obtained multiplying the num-
















this habit. A smoker was considered when the person is an 
active cigarette consumer with a Brinkman index equal or 
above 80118, and a recent former smoker (less than a year) 
were also categorized as smoker. A non-smoker was de-
fined as the person to have never smoked or not achieving 
a positive index value.
Socioeconomic status: It was studied applying the Graffar 
scale modified by Mendez Castellano19, whose criteria are 
as follows: a. profession of the head of the family, b. in-
struction level of the mother, c. source of income, and d. 
housing conditions. The strata were defined according to 
the score obtained from the arithmetic sum of each crite-
rion; having then: Stratus I (high class), Stratus II (medium 
high class), Stratus III (me dium class), Stratus IV (working 
class), and Stratus V (extreme poverty). Such a scale was 
developed for the Venezuelan population, but it has been 
validated and used in other LA studies where the unequal 
economic, cultural, and social levels are evident, and influ-
ence social behavior, growth, alimentary habits, and bio-
logic development.
Physical activity: As a tool for evaluating physical activ-
ity (PA), the International Physical Activity Ques tionnaire 
(IPAQ)20 was used. It is a tool that has been extensively used 
in clinical and epidemiologic studies to assess physical ac-
tivity in countries with different cultures and sociocultural 
classes. It is based on the physical activity preformed in the 
last 7 days, and it takes into account 4 elements of evalua-
tion: a. physical activity in leisure time, b. domestic and gar-
dening activities, c. physical activity related to work, and d. 
physical activity related to transport. IPAQ scoring consider 
3 PA levels: low, moderate, and high, using as measuring 
unit the metabolic equivalent, defined by the energy con-
sumption of an individual in a resting state, which is 1 kcal/
kg/hour approximately (4.184 kJ/kg/hour)21.
Race: Many concepts of ethnicity/race have been devel-
oped, and most of them have been controversial. The 
definitions tend to classify human groups according to 
socio-anthropo logic customs and cultural aspects of each 
homogeneous human cluster, without taking into account 
its genetic back ground. In biomedicine, there is a clear 
relation ship between racial groups and the aggregation 
of some diseases. In this matter, several studies have been 
con ducted using this ethnic classification22: a. Amer indians 
or American Aborigines, b. mixed race, c. Afro-Americans, 
d. Orientals, e. Hispanic Whites and f. Arabs.
Alcohol Consumption: The American Heart As sociation17 
criteria are taken into account to consider if a person is a 
drinker or not. An alcohol drinker was considered when 
that individual drank over 30 g of alcohol (2 glasses of wine 
or its equivalent) per day, or, 210 g of ethanol per week. 
The CAGE23 and AUDIT24 test was applied to detec t alco-
hol related problems, Nutritional status evaluation: They 
were defined by a vali dated questionnaire25; and for this 
purpose, the examination was divided into 2 parts: (a) 24 
hours recall and (b) listing of alimentary preferences and 
consumption frequency. From these data, alimentary pref-
erences, daily calories obtained from carbohydrates, lipids, 
proteins, micro-nutrients and the approximate ingestion of 
hydro philic and lipidic vitamins, daily ingestion of choles-
terol, saturated fats, mono, and polyunsat urated fats will 
be calculated26.
Blood Pressure Measuring: It will be done using the auscul-
tatory method for which a calibrated sphygmomanometer 
will be used. The patients will be sitting still—with their 
feet on the ground—for less than 15 minutes before the 
determination. During the procedure, the arm will be at 
the same level of the heart, being the systolic pressure the 
first sound that is heard (phase 1) and diastolic pressure the 
point where the sound fades (phase 5). The procedure will 
be done 3 times, 15 minutes apart from each other, and at 
least, in 2 different days27,28. 
Basic Anthropometry: A. Waist circumfer ence (WC) and 
Waist-to-hip ratio29 will be assessed using a plastic measur-
ing tape graded in centimeters and millimeters, in a spot 
equidistant to the lower ribcage border and the anterior–
superior iliac spine. B. Height will be measured using a 
metal height measurer graded in centimeters. The results 
will be converted to meters dividing the result into 10. C. 
Body mass index will be calculated applying the equation: 
weight over square height (kg/(height)2 in meters30. D. Neck 
Circumference (NC) will be measured in the midway of the 
neck, between midcervical spine and midanterior neck, to 
within 1 mm31. 
Impedanciometric Measures: It will be under taken using a 
digital 2 electrode impedanciometer (TBF-310GS, Tanita, 
Japan). The protocol involved previous preparation aiming 
to standardize the hydration status to undergo the BIA as-
sessment and consisted of the following: be at least seven 
days after the last menstrual period and seven days be-
fore the next; undergo complete fasting in the previous 
12 hours; refrain from physical exercises in the previous 12 
hours; no alcohol consumption in the previous 48 hours; 
no use of diuretics for at least seven days before the assess-
ment; and urination 30 Minutes before the assessment32-34. 
Laboratory Analysis: After 8-12 hours of fasting, serum lev-
els of total cholesterol, triacylglycerides (TAG), HDL-C and 
basal glycemia will determined using computerized equip-
ment (Human Gesellschoft Biochemica and Diagnostica 
MBH, Magdeburg, Germany). The time between sample 
taken and its processing never will exceed 3 months. Low 
density lipoprotein (LDL) levels will be calculated using the 
Fridewald equation if triacylglycerides levels are below 400 
mg/dL, and if they are above, they will be determined by 
electrophoresis of lipoproteins in agarose gel and ulterior 
band densimetry (GS-800 densitometer, Bio-Rad, Hercules, 
CA). Fasting insulin will be quantified using a commercial 
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ultrasensitive ELISA-based kit (DRG international. Inc. USA. 
New Jersey), with a detection limit of <1 mU/L. HOMA2-
IR and HOMA2-bcell models will be calculated using the 
HOMA Calculator35. Likewise, Lipoprotein(a) [Lp(a)] con-
centration will be determined using the turbidimetric latex 
method (Human Gesellschoft Biochemica and Diagnostica 
MBH, Magdeburg, Germany) with a threshold of ≥30 mg/
dL. High sensivity C-Reactive Protein (hs-CRP) will be as-
sessed employing turbidmetric immune essays (Human Ge-
sellschoft Biochemica and Diagnostica MBH, Magdeburg, 
Germany). Finally, serum TSH, FT3 and FT4 concentration 
will be determined using a commercial ELISA kit (DRG In-
ternational Inc. USA). Subclinical Hypothyroidism diagno-
sis was made according to NHANES criteria: normal levels 
of FT4 (0.9-1.9 ng/dL) with an elevated TSH level (≥4.12 
mUI/L) and absence of prior personal history of thyroid 
disease36. Anti-TPO and anti-tiroglobulin antibodies will be 
quantified by ultra-sensitive ELISA method.
Neurocognitive evaluation: this will be assessed using the 
Alzheimer’s Early Detection test proposed by Cuetos-Vegas 
et al.37, using a 10 memory task survey.
Metabolic Syndrome definitions
The MetS diagnostic criteria used in this study will be:
1. Harmonized IDF-2009 classification (require 3 of the 
following 5 variables):
a) Elevated WC (Men ≥90 cm and Women ≥80 cm); b) 
Hypertriacylglyceridemia ≥150 mg/dL or specific treat-
ment for this abnormality; c) Low HDL-C, Men <40 mg/
dL, Women <50 mg/dL or specific treatment for this 
abnormality; d) Elevated Blood Pressure, Systolic ≥130 
mmHg, Diastolic ≥85 mmHg, or previous diagnosis of 
hypertension; e) Elevated Fasting Glucose, Glycemia 
≥100 mg/dL or drug treatment for hyperglycemia15.
2. The IDF-2005 classification stated the following: man-
datory elevated WC (Men ≥90 cm and Women ≥80 cm) 
plus any two of the following: a) Hypertriacylglyceride-
mia ≥150 mg/dL or specific treatment for this abnor-
mality; b) Low HDL-C, Men <40 mg/dL and Women 
<50 mg/dL or specific treatment for this abnormality; c) 
Elevated Blood Pressure, Systolic ≥130 mmHg, Diastolic 
≥85 mmHg, or previous diagnosis of hypertension; d) 
Elevated Fasting Glucose, with Impaired Fasting Glyce-
mia ≥100 mg/dL or previous diagnosis of T2DM8.
3. The ATPIII-2005 classification require 3 of the follow-
ing 5 components: a) Elevated WC (Men ≥102 cm and 
Women ≥88 cm); b) Hypertriacylglyceridemia ≥150 mg/
dL or specific treatment for this abnormality; c) Low 
HDL-C, Men <40 mg/dL, Women <50 mg/dL or spe-
cific treatment for this abnormality; d) Elevated Blood 
Pressure, Systolic ≥130 mmHg, Diastolic ≥85 mmHg, or 
previous diagnosis of hypertension; e) Elevated Fasting 
Glucose: Glycemia ≥100 mg/dL or drug treatment for 
hyperglycemia14,38.
Supervising procedures
Supervision of the data quality will be done in all the levels 
of the processing. The evaluation from each coordinator at 
each level assured that the data recollection was accord-
ing to protocol. The monitoring of equipment, including 
mercury sphygmomanome ters, was verified and calibrated 
periodically through out the whole project.
Data processing
The arrival and processing of all the data will be done within 
the CIEM and AEF. The medical history and various data will 
be physically stored and their information digitalized. The 
processing personnel were capacitated in the proper use of 
the programs, and all the data were inserted in duplicates 
to obtain higher security in the process. An audit data base 
process will be done in 20% of the SPSS patient´s data grid.
Statistical analysis
Study forms were reviewed to ensure that they were com-
plete before data entry. Data will be entered by duplicate 
into SPSS 22.0 (SPSS Inc., IBM Chicago, IL) for Windows 
spreadsheets and compared using Epi-Info 2000 (CDC, 
Atlanta, GA). Any discrepancy was cor rected using the 
original study record. Qualitative variables will be expressed 
as absolute and relative frequencies and their potential 
association will be evaluated by the χ2 (Chi square) test 
and the difference between proportions will be assessed 
with the Z Test. Quantitative variables distribution will be 
evaluated by the Geary´s test and those with not normal 
distribution will be submitted to logarithmic transforma-
tion. The quantitative variables were expressed as arithme-
tic means ± standard deviation (SD), except CRP-us which 
will be expressed as median and p25-p75. t-Student test 
and one-way ANOVA with Tukey´s post-hoc analysis will be 
employed in order to assess differences between arithmetic 
means. For medians comparisons the Mann-Whitney´s U 
test will be employed.
The association between components of MetS and the Ho-
meostasis Model Assessment index and other quantitative 
n-tiles will be analyzed through a logistic regression model 
considering adjustments by cluster ing effect. The degree 
of concordance between SM classifications was deter-
mined employing both, the Cohen’s Kappa coefficient and 
the Landis-Koch´s assessment scale39,40. This scale covey 
a classification for kappa agreement results: a) <0,00: no 
agreement; >0,00-0,20: insignificant; 0,21-0,40: discreet; 
>0,41-0,60: moderate; 0,61-0,80: substantial; 0,81-1,00: 
near perfect. The data were analyzed employing the Statis-
tical Package for Social Sciences ver. 22 for Windows (SPSS 




The study protocol was designed in compliance with the 
Helsinki declaration and approved by the Research Ethics 
Board from the CIEM and ALEF. Consent was obtained 
from all participants as mentioned above.
n 1999, the World Health Organization (WHO) con-
sultant group published the first MetS definition41, 
whose principal aspect was the biologic and physi-
ologic description of the insulin resistance as the main fea-
ture of this entity. It was also recognized that CVD was 
the primary adverse outcome of the syndrome. Afterward, 
other MetS definitions came to the spotlight, for example, 
The European Group for the study of Insulin Resistance42 in 
1999, The National Cholesterol Educa tion Program/Adult 
Treatment Panel III (ATP III) in 200114 (which was popular 
due to its simplicity), The American Association of Clinical 
Endocrinol ogists MetS diagnostic criteria43, and many oth-
ers. Yet, it was not until 2005 that the International Dia-
betes Federation (IDF) founded a con sensus group whose 
purpose was to establish a new definition for MetS that 
could be used in epidemiologic and clinical trials all around 
the world. They proposed that central obesity is the man-
datory requisite that was necessary to make the diagnosis, 
and for the first time, cut-off values for WC were offered 
for different ethnic groups8.
Knowing previous statements, one of the most important 
observations to IDF classification resides in cut-off points for 
each studied variable because LA countries have no popu-
lation studies that could establish a proper cut-off point to 
numerically separate a normal from abnormal value, and 
of course, the attributable risk to each variable measure. 
In fact, IDF asks that any investigator in need of such val-
ues—for abdominal circumference, for example—must 
assume that Eastern Asians cohort data are good enough 
for research purposes in LA context. This simple sugges-
tion is quite delicate because there are few studies in our 
countries evaluating MetS behavior; so applying Asian data 
could be wrong in the sense of lack of concordance be-
tween ethnic groups. That is why one of the goals of this 
trial is to shed some evidence on the epidemiologic aspects 
of MetS taking as pattern the IDF and ATP III classifica tions, 
and afterward, to be able to set cut-off points in accor-
dance to the peculiarities of our population. 
Despite this weakness, some research groups have explored 
the epide miologic behavior of MetS in Hispanic whites and 
mixed LA groups. For instance, in 2005, the Metabolic Syn-
drome in Active Subjects (MESYAS) study was conducted 
in 7256 active Spanish workers. They applied the ATP III cri-
teria for MetS diagnosis, revealing a prevalence of 10.2%, 
and it was associated with age, male gender, obesity di-
agnosis, hypertension, and/or diabetes mellitus. These re-
sults indicate that 1 out of every 10 workers had MetS44. 
The Mexican National Health and Nutrition Survey 2006 
reported a MetS prevalence in Mexican adults aged 20 
years or older according ATP III-2001, ATP-2005, and the 
International Diabetes Federation (IDF) definitions of 36.8, 
41.6 and 49.8%, respectively. A similar trend is observed 
in Talca, Chile, based on a study done in 2007, where high 
cardiovascular risk factors prevalence compared with what 
was observed during the National Health Survey of 2003. 
In the 2007 study, 1007 individuals who were 18–74 years 
old were used as population sample (with 66% women), 
showing an elevated percentage of smoking individu-
als (70.1%), and obese/overweight subjects (45%). High 
blood pressure was present (37%), along with hypercholes-
terolemia (44.5%), low c-HDL (21.5%), and hypergly cemia 
(26.3%). The prevalence of metabolic syndrome according 
to the IDF and ATP III criteria was 36.4% and 29.5%, re-
spectively after adjustment for age and sex45. This allows 
us to see that there is an array of environmental factors 
and life style issues that LAs people are living with that en-
hances the risk for such disorders.
More recently, a work from Scuteri et al. from the Metabolic 
Syndrome and Arteries Research (MARE) Consortium made 
in 12 cohorts from 10 European countries and one cohort 
from the USA (34,821 subjects), the prevalence of MetS 
according 2001 ATP III criteria was 24.3% (8468 subjects: 
23.9% in men vs. 24.6% in women, p < 0.001) with an 
age associated increase in its prevalence in all the cohorts46. 
The risk factors for MetS and its components have been 
poorly investigated in a Latin America context, indeed, only 
one study assessed MetS behavior in a multi-country con-
text, the Cardiovascular Risk Factor Multiple Evaluation in 
Latin America study (CARMELA), a cross-sectional trial com-
prised individuals (n: 11,550) aged 25 to 64 years, living in 
Barquisimeto, Bogota, Buenos Aires, Lima, Mexico City, 
Quito, and Santiago that investigated CVD risk factors and 
MetS prevalence. The investigators found that MetS was 
most prevalent in Mexico City (27%) and Barquisimeto 
(26%), followed by Santiago (21%) and Bogota (20%); 
lower prevalence was found in Lima (18%), Buenos Aires 
(17%), and Quito (14%). Overall, metabolic syndrome was 
more prevalent in women than men (22% vs 20%, respec-
tively), with the exception of Buenos Aires and Barquisime-
to where more men than women had metabolic syndrome. 
As expected, the prevalence of MetS increased with age. 
In all cities, women showed markedly greater increase in 
metabolic syndrome with increasing age than men; in the 
oldest age group, female prevalence (range 25% to 49%) 
was greater than male prevalence (range 13% to 38%) 
in all cities except Buenos Aires. Of the components of 
MetS, the abdominal obesity was notably more prevalent 
in women than men, and the difference was accentuated 
in successively older age groups11,47. In a recent investiga-
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City Metabolic Syndrome Prevalence Study13, a cross-sec-
tional study conducted in a representative sample of 2.230 
adult individuals from Maracaibo, Venezuela. ATPIII-2005, 
IDF-2005 and harmonized IDF-2009 MetS criteria were 
employed to analyze MetS prevalence and the agreement 
levels of these classification systems. The investigators 
found a MetS prevalence of 42,4%, 41,6% and 35,5% 
according harmonized IDF-2009, IDF-2005 and ATPIII-2005 
respectively. The agreement level between harmonized IDF-
2009 and ATPIII-2005; IDF-2005 and ATPIII-2005 and IDF-
2005 and harmonized IDF-2009, exhibited a kappa index 
of k=0.98 (p<0,000001); k=0.86 (p<0,00001) and k=0.84 
(p<0,0001) respectively9,13,48.
Although there have been studies that have assessed the 
prevalence of MetS in Colombia, these have been conduct-
ed in specific subgroups, such as a study in college students 
by Alfonso et al. in 249 young individuals admitted to the 
National University of Colombia in Bogotá49 with a MetS 
prevalence of 2,4%, or the work of Arteaga et al, 2010 in 
a sample of 614 civilian aircraft pilots (MetS prevalence of 
6%)50. An exception of this landscape is the work of Davila 
et al, 2013 whom assessed the prevalence and risk factors 
for metabolic syndrome (MetS) among adults from Medel-
lin and surrounding municipalities in a sample of 3.000 
adult individuals. Of these, 21.4% had high blood pressure 
(HBP) and 64% had abdominal obesity. In the subsample 
with serum data (n=943), 19.8% had high fasting serum 
glucose, 43.9% had high triglycerides (HTG), 56.6% had 
low c-HDL and a MetS overall prevalence of 41%. Increas-
ing age was associated with MetS and all components ex-
cept low c-HDL51. 
There is clear evidence that there is a lack of research and 
validated values to use as reference in our study. Even 
though the IDF suggested that when studying LA popula-
tion, they should rely on Asian data. Taking into account all 
that has been exposed here, we strongly believe that the 
results of this study will help establish globally acceptable 
criteria for the early detection and in tervention of MS in 
urban population of Colombia. Moreover, they will provide 
policy makers, health care providers, and educators from a 
developing country like Colombia with an opportunity to 
guide primary and secondary preventive initiatives at indi-
vidual and community levels.
Finally, this work will serve as a pilot study for the numer-
ous statistical and epidemiologic investigations that will 
come afterward, providing first hand accurate evidence 
on the behavior of the MS and its components in our city 
population.
ACKNOWLEDGMENTS
This work is supported by research project N° C3031720916 
from the Altos Estudios de Frontera (ALEF) research group. 
Simón Bolívar University, Cúcuta, República de Colombia.
 
1.  Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic 
Syndrome and Risk of Incident Cardiovascular Events and Death. J Am Coll Car-
diol. 2007 Jan;49(4):403–14. 
2.  Galassi A, Reynolds K, He J. Metabolic Syndrome and Risk of Cardiovascular Dis-
ease: A Meta-Analysis. Am J Med. 2006 Oct;119(10):812–9. 
3.  Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associ-
ated with the metabolic syndrome a summary of the evidence. Diabetes Care. 
2005;28(7):1769–1778. 
4.  Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, et al. Metabolic syn-
drome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes 
the Casale Monferrato study. Diabetes Care. 2004;27(11):2689–2694. 
5.  Malik S. Impact of the Metabolic Syndrome on Mortality From Coronary Heart 
Disease, Cardiovascular Disease, and All Causes in United States Adults. Circula-
tion. 2004 Sep 7;110(10):1245–50. 
6.  Cameron AJ, Boyko EJ, Sicree RA, Zimmet PZ, Söderberg S, Alberti KGMM, et al. 
Central Obesity as a Precursor to the Metabolic Syndrome in the AusDiab Study 
and Mauritius. Obesity. 2008 Dec;16(12):2707–16. 
7.  Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US 
adults: findings from the third National Health and Nutrition Examination Survey. 
Jama. 2002;287(3):356–359. 
8.  Alberti K, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. 
A Consensus Statement from the International Diabetes Federation. Diabet Med. 
2006;23(5):469–480. 
9.  Bermúdez V, Rojas J, Salazar J, Calvo MJ, Morillo J, Torres W, et al. The Maracaibo 
city metabolic syndrome prevalence study: primary results and agreement level of 
3 diagnostic criteria. Rev Latinoam Hipertens. 2014;9(4):20–32. 
10.  Bermúdez VJ, Finol FJ, Leal N, Parra MG, Peñaranda LP, Pérez AC, et al. Prevalencia 
del síndrome metabólico en la población adulta Añú de la laguna de Sinamaica 
del Municipio Páez, estado Zulia. Rev Latinoam Hipertens. 2009;4(3):64–70. 
11.  Schargrodsky H, Hernández-Hernández R, Champagne BM, Silva H, Vinueza R, 
Silva Ayçaguer LC, et al. CARMELA: Assessment of Cardiovascular Risk in Seven 
Latin American Cities. Am J Med. 2008 Jan;121(1):58–65. 
12.  Márquez-Sandoval F, Macedo-Ojeda G, Viramontes-Hörner D, Fernández Ballart 
J, Salas Salvadó J, Vizmanos B. The prevalence of metabolic syndrome in Latin 
America: a systematic review. Public Health Nutr. 2011 Oct;14(10):1702–13. 
13.  Bermudez V, Marcano RP, Cano C, Arráiz N, Amell A, Cabrera M, et al. The Ma-
racaibo city metabolic syndrome prevalence study: design and scope. Am J Ther. 
2010;17(3):288–294. 
14.  Expert Panel on Detection E. Executive Summary of the Third Report of the Na-
tional Cholesterol Education Program (NCEP) Expert Panel on Detection, Evalua-
tion, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 
III). JAMA. 2001 May 16;285(19):2486–97. 
15.  Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. 
Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the Interna-
tional Diabetes Federation Task Force on Epidemiology and Prevention; National 
Heart, Lung, and Blood Institute; American Heart Association; World Heart Fed-
eration; International Atherosclerosis Society; and International Association for 
the Study of Obesity. Circulation. 2009 Oct 20;120(16):1640–5. 
16.  Inicio [Internet]. [cited 2015]. Available from: http://formularios.dane.gov.co/
Anda_4_1/index.php/home
17.  NHANES - NHANES III Web Tutorial - Sample Design [Internet]. [cited 2015]. Avail-
able from: http://www.cdc.gov/nchs/tutorials/nhanes/SurveyDesign/SampleDe-
sign/intro_iii.htm
18.  Brinkmann GL and Coates EO, Jr. The Cumulative number of cigarettes predicts 
diabetes effect of bronchitis, smoking, and occupation on ventilation. 87: 684-
693. Am Rev Respir Dis. 1963;87:684–93. 
19.  Méndez Castellano, Hernán y Méndez, María Cristina de. Sociedad y estratifi-
cación : método graffar-Méndez Castellano. Venezuela: FUNDACREDESA; 1994. 
206 p. 
20.  Craig CL, Marshall AL, Sj??Str??M M, Bauman AE, Booth ML, Ainsworth BE, et al. 
International Physical Activity Questionnaire: 12-Country Reliability and Validity: 
Med Sci Sports Exerc. 2003 Aug;35(8):1381–95. 
21.  International Physical Activity Questionnaire [Internet]. [cited 2015]. Available 
from: https://sites.google.com/site/theipaq/
22.  Fernández WMZ, Borjas-Fajardo L, Salgado EF, Castillo C, Socca L, Portillo MG, 
et al. Use of short tandem repeats loci to study the genetic structure of several 
populations from Zulia State, Venezuela. Am J Hum Biol. 2005 Jul;17(4):451–9. 




24.  Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. Audit. Alco-
hol Use Disord Identif Test AUDIT Guidel Use Prim Care [Internet]. 2001 






25.  Automated Self-Administered 24-Hour (ASA24®) Dietary Assessment Tool [Inter-
net]. [cited 2015]. Available from: http://epi.grants.cancer.gov/asa24//
26.  Schatzkin A, Kipnis V, Carroll RJ, Midthune D, Subar AF, Bingham S, et al. A 
comparison of a food frequency questionnaire with a 24-hour recall for use in an 
epidemiological cohort study: results from the biomarker-based Observing Protein 
and Energy Nutrition (OPEN) study. Int J Epidemiol. 2003 Dec 1;32(6):1054–62. 
27.  Ogedegbe G, Pickering T. Principles and Techniques of Blood Pressure Measure-
ment. Cardiol Clin. 2010 Nov;28(4):571–86. 
28.  O’Brien E, Pickering T, Asmar R, Myers M, Parati G, Staessen J, et al. Working 
Group on Blood Pressure Monitoring of the European Society of Hypertension In-
ternational Protocol for validation of blood pressure measuring devices in adults. 
Blood Press Monit. 2002;7(1):3–17. 
29.  World Health Organization. Waist circumference and waist-hip ratio: report of a 
WHO expert consultation, Geneva, 8-11 December 2008. Geneva: World Health 
Organization; 2011. 
30.  Ma W-Y, Yang C-Y, Shih S-R, Hsieh H-J, Hung CS, Chiu F-C, et al. Measurement 
of Waist Circumference: Midabdominal or iliac crest? Diabetes Care. 2013 Jun 
1;36(6):1660–6. 
31.  Ben-Noun L (Louba), Sohar E, Laor A. Neck Circumference as a Simple Screening 
Measure for Identifying Overweight and Obese Patients. Obes Res. 2001 Aug 
1;9(8):470–7. 
32.  Kyle U. Bioelectrical impedance analysis?part I: review of principles and methods. 
Clin Nutr. 2004 Oct;23(5):1226–43. 
33.  Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Manuel Gómez J, et al. 
Bioelectrical impedance analysis—part II: utilization in clinical practice. Clin Nutr. 
2004 Dec;23(6):1430–53. 
34.  Buchholz AC, Bartok C, Schoeller DA. The Validity of Bioelectrical Impedance 
Models in Clinical Populations. Nutr Clin Pract. 2004 Oct 1;19(5):433–46. 
35.  HOMA Calculator : Download [Internet]. [cited 2015]. Available from: https://
www.dtu.ox.ac.uk/homacalculator/download.php
36.  Spencer CA, Hollowell JG, Kazarosyan M, Braverman LE. National Health and 
Nutrition Examination Survey III Thyroid-Stimulating Hormone (TSH)-Thyroper-
oxidase Antibody Relationships Demonstrate That TSH Upper Reference Limits 
May Be Skewed by Occult Thyroid Dysfunction. J Clin Endocrinol Metab. 2007 
Nov;92(11):4236–40. 
37.  Cuetos-Vega F, Menéndez-González M, Calatayud-Noguera T. Descripción de un 
nuevo test para la detección precoz de la enfermedad de Alzheimer. Rev Neurol. 
2007;44(8):469–474. 
38.  Grundy SM. Diagnosis and Management of the Metabolic Syndrome: An Ameri-
can Heart Association/National Heart, Lung, and Blood Institute Scientific State-
ment. Circulation. 2005 Oct 25;112(17):2735–52. 
39.  Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical 
Data. Biometrics. 1977 Mar;33(1):159. 
40.  Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and 
sample size requirements. Phys Ther. 2005;85(3):257–268. 
41.  Alberti KGMM, Zimmet P ft. Definition, diagnosis and classification of diabetes 
mellitus and its complications. Part 1: diagnosis and classification of diabetes mel-
litus. Provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–
553. 
42.  Balkau B, Charles M. Comment on the provisional report from the WHO consul-
tation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 
1999;16:442–3. 
43.  Einhorn D. American College of Endocrinology position statement on the insulin 
resistance syndrome*. Endocr Pract. 2003;9(Supplement 2):5–21. 
44.  Alegría E, Cordero A, Laclaustra M, Grima A, León M, Casasnovas JA, et al. Preva-
lencia del síndrome metabólico en población laboral española: registro MESYAS. 
Rev Esp Cardiol. 2005;58(7):797–806. 
45.  Mujica V, Leiva E, Icaza G, Diaz N, Arredondo M, Moore-Carrasco R, et al. Eval-
uation of metabolic syndrome in adults of Talca city, Chile. Nutr J. 2008 May 
15;7:14. 
46.  Scuteri A, Laurent S, Cucca F, Cockcroft J, Cunha PG, Manas LR, et al. Metabolic 
syndrome across Europe: Different clusters of risk factors. Eur J Prev Cardiol. 2015 
Apr 1;22(4):486–91. 
47.  Escobedo J, Schargrodsky H, Champagne B, Silva H, Boissonnet CP, Vinueza R, 
et al. Prevalence of the Metabolic Syndrome in Latin America and its association 
with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study. Car-
diovasc Diabetol. 2009;8(1):52. 
48.  Valmore Bermúdez MD, Añez R, Salazar J, Bello L, Toledo A, Chacín M, et al. 
Metabolic Syndrome components combinations: evidence of asymmetric cluster-
ing determined by central obesity and homeostasis model assessment/Combina-
ciones de los componentes de Síndrome Metabólico: evidencia de agrupación asi-
métrica determinado por obesidad central y HOMA. Sindrome Cardiometabólico. 
2014;4(4):100. 
49.  Feliciano-Alfonso JE, Mendivil CO, Ariza IDS, Pérez CE. Cardiovascular risk factors 
and metabolic syndrome in a population of young students from the National 
University of Colombia. Rev Assoc Médica Bras. 2010;56(3):293–298. 
50.  Arteaga-Arredondo LF, Fajardo-Rodríguez HA. Prevalencia de factores de riesgo 
cardiovascular en pilotos de aviación civil en Colombia en el aÃ$\pm$o 2005. Rev 
Salud Pública. 2010;12(2):250–256. 
51.  Davila EP, Quintero MA, Orrego ML, Ford ES, Walke H, Arenas MM, et al. Preva-
lence and risk factors for metabolic syndrome in Medellin and surrounding mu-
nicipalities, Colombia, 2008–2010. Prev Med. 2013 Jan;56(1):30–4. 
Manuel Velasco (Venezuela) Editor en Jefe  -  Felipe Alberto Espino Comercialización y Producción
Reg Registrada en los siguientes índices y bases de datos: 
SCOPUS, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, 
OPEN JOURNAL SYSTEMS (OJS), REDALYC (Red de Revistas Científicas de América Latina, el Caribe, España y Portugal), 
LATINDEX (Sistema Regional de Información en Línea para Revistas Científicas de América Latina, el Caribe, España y Portugal)
LIVECS (Literatura Venezolana para la Ciencias de la Salud), LILACS (Literatura Latinoamericana y del Caribe en Ciencias de la Salud)
PERIÓDICA (Índices de Revistas Latinoamericanas en Ciencias), REVENCYT (Índice y Biblioteca Electrónica de Revistas Venezolanas de Ciencias y Tecnología)
SCIELO (Scientific Electronic Library Online), SABER UCV, DRJI (Directory of Research Journal Indexing)
CLaCaLIA (Conocimiento Latinoamericano y Caribeño de Libre Acceso), EBSCO Publishing, PROQUEST.
